Tag: stock

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) today jointly announce that the New Drug Application (“NDA”) for the combination of fruquintinib and sintilimab for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment with one tyrosine kinase inhibitor (“TKI”) has been accepted for review by the China National Medical Products Administration (“NMPA”).

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.


Frøya, 5 June 2025: Reference is made to the stock exchange release from Kaldvík AS (the "Company") published on 4 June 2025 regarding a contemplated private placement to raise gross proceeds of the NOK equivalent of approximately EUR 46.2 million (the "Private Placement") by the issuance of new shares in the Company (the "Offer Shares"). The Company hereby announces that it has raised approximately NOK 532 million, equivalent to approximately EUR 46.2 million, in gross proceeds through a private placement of 38,011,050 new shares (the "New Shares") at a price per share of NOK 14 (the "Offer Price"). The Private Placement took place through an accelerated bookbuilding process managed by DNB Carnegie, a part of DNB Bank ASA ("DNB Carnegie") as Sole Global Coordinator and Joint Bookrunner and Arion Banki hf ("Arion") and Nordea Bank Abp, filial i Norge ("Nordea") as Joint Bookrunners for the Private Placement (jointly, the "Managers").

COOTAMUNDRA, Australia, June 04, 2025 (GLOBE NEWSWIRE) -- Australian Oilseeds Holdings Limited (the “Company”) (NASDAQ: COOT), a manufacturer and seller of sustainable edible oils to customers globally, announced that it has received written notification from the Nasdaq Stock Market LLC (“Nasdaq”) on May 27, 2025 stating that the Company was delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2025. The Company previously filed a Form 12b-25 with the U.S. Securities and Exchange Commission on May 14, 2025, disclosing that it was unable to file the Form 10-Q within the prescribed time period without unreasonable effort or expense. The Nasdaq Letter provided that under Nasdaq rules, the Company has 60 calendar days to submit a plan to regain compliance with respect to the Delinquent Filing.

CALGARY, Alberta , June 04, 2025 (GLOBE NEWSWIRE) -- Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GTE) (TSX:GTE) (LSE:GTE) today announced that a wholly owned subsidiary of the Company has signed an agreement to sell its wholly owned subsidiary, Gran Tierra North Sea Limited (“GTNSL”), to NEO Energy for total consideration of US$7.5 Million. NEO Energy is a private upstream company and a leading independent operator in the United Kingdom Continental Shelf.

TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- AGF Management Limited (TSX: AGF.B) will release its financial results for Q2 2025 on Wednesday, June 25, 2025 at approximately 7:00 a.m. ET. AGF will hold a conference call and webcast to discuss these results at 11:00 a.m. ET.

Investors can contact the law firm at no cost to learn more about recovering their losses

TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- AGF Management Limited reported total assets under management (AUM) and fee-earning assets¹ of $53.5 billion as at May 31, 2025.

BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on June 2, 2025, the Compensation Committee of Praxis’ Board of Directors granted a restricted stock unit award covering 750 shares of its common stock to one new non-executive employee under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit award was granted as inducement material to the employee’s entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

Highlights

Investors can contact the law firm at no cost to learn more about recovering their losses

Investors can contact the law firm at no cost to learn more about recovering their losses

IOVA Investors with Losses Encouraged to Contact Hagens Berman